article thumbnail

Amgen Abandons Alzheimer's Prevention Study

socalTECH

Thousand Oaks-based Amgen , along with partners Novartis and the Banner Alzheimer's Institute , said late last week that they are discontinuing a clinical research program, which had focused on Alzheimer's prevention. READ MORE>>.

Study 113
article thumbnail

Amgen Reports Positive Results In Ostereoposis Study

socalTECH

Thousand Oaks-based Amgen reports that it saw positive top-line results for a study for its romosozumab compound in men with osteoporosis. Amgen said its Phase 3 study demonstrated a significant increase in bone mineral density (BMD) at the lumbar spine, compared with a placebo over 12 months.

Study 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen, Merck Team On Cancer Immmunotherapy Studies

socalTECH

Thousand Oaks-based Amgen and fellow biopharmaceuticals giant Merck said today that they are in a cancer immunotherapy collaboration, to support a Phase 1b/3 study. The two said the study includes both Amgen's BLINCYTO (blinatumomab) product and Merck's EKYTRUDA (pemblizumab) therapy, for treating non-Hodgkin lymphoma.

Study 100
article thumbnail

Amgen Ties With Piper Jordan On Migraine Management

socalTECH

Thousand Oaks-based biotech giant Amgen said this morning that it has tied with Piper Jordan , a health and benefit consulting firm, to launch a new disease management program for people living with migraine.

article thumbnail

Teledyne Wins $10M Contract For Sensors For Mission to Jupiter

socalTECH

Thousand Oaks-based Teledyne Technologies said late Monday afternoon that Teledyne Scientific & Imaging, one of its subsidiaries, has been awarded $9.98M in a contract from the French Space Agency, the Centre National d'Etudes Spatiales (CNES), to support a mission to Jupiter. the JUICE mission is expected to reach Jupiter in 2030.

article thumbnail

Amgen Licenses Rights To Multiple Myeloma Drug

socalTECH

Thousand Oaks-based Amgen and Boehringer Ingelheim said on Thursday that Amgen has acquired the global development and commercial rights for an immuno-oncology drug for treating multiple myeloma. The compound is currently in Phase I studies. Financial details of the deal were not announced. READ MORE>>.

article thumbnail

Amgen Sees Clinical Trial Failure, Recall

socalTECH

Thousand Oaks-based Amgen reported Wednesday that its Phase 3 clinical trial for its compound Kyprolis--which was being targeted for treatment of multiple myeloma--has failed, and that the study has been discontinued.